Take a look at Robert Kelly’s AI driven HR tool.

The sheer number and rapid increase in the number of (often duplicative) mandatory online training modules for clinical care, research, and institutional employment is completely unsustainable ⁦AMA⁩ ama-assn.org/practice-manag…

Dear Students, Trainees, and Early-Career Oncologists,

We put together these tips to advice on how to plan your ASCO annual meeting!

⭐️ Grow professionally and have fun!

ASCO ASCOTECAG ASCOPres Jacob J. Adashek, DO Cissa Mathias #ASCOConnection

connection.asco.org/tec/career/mak…

🚨Save the date 🚨
ASCO IMG COP IMG Oncologists - Visa, Mentorship & Advocacy Committee's webinar💥 J1 visa holders pursuing academic career💥

⏰ April 23rd, 6 PM EST

💥Guests Patrick Forde , Maya K. Khalil, MD & David Nachman
Host Mamtha Balla,MD, MPH, FACP
ASCO IMG CoP 👉bit.ly/3JmJQwK

BREAKING: FTC and DOJ Antitrust Division opened new portal to hear about the monopolies controlling healthcare and stifling competition. Please take a minute and make them aware of the ABMS monopoly!
Westby Fisher, MD Aaron Goodman - “Papa Heme” chadi nabhan MD, MBA, FACP Marty Makary MD, MPH Vinay Prasad MD MPH

Submit a…

10 suggested action items for physician colleagues suffering under the burden of American Board of Internal Medicine (ABIM) MOC. #MedTwitter

1. If your institution allows it, stop participating in MOC. Personally, MOC has no value to me.

sobre las causas de ser zurdos
blogs.elespectador.com/actualidad/cat…

Disease X has poor prognosis.
Which is sad.

BUT that does NOT automatically mean

Therefore, let’s lower the standard for disease X and approve all drugs.

Sometimes, we harm the patients (and always, we harm the system) by lowering the bar simply because the disease is bad.

A team of researchers from Stanford Cancer Institute, City of Hope and . UCLA Broad Stem Cell has received a $10.2 million CIRM grant that will fund its CAR T-cell therapy clinical trial for patients with melanoma and advanced solid tumors. ➡️ bit.ly/4aPEciA

➡️DIVERSITY should be addressed early in development

➡️Diversity Plans (DPs) MUST be developed by sponsors to inform oncology clinical trial framework

Very nice discussion of DPs w/ FDA Oncology & multiple stakeholders at #AACR24 AACR Love always hearing patient perspectives

⁦Westby Fisher, MD⁩ and I are gonna sue the ABIM as we had enough. Dr Fisher has been at this for years and it’s time we all pitch in and help. Consider donating anything for this law suit!

Fundraiser Practicing Physicians of America by Westby G. Fisher : gofundme.com/f/practicing-p…

Public Service Announcement!

I urge all sub specialists to drop their IM board to avoid paying late fees. ABIM ties IM board to subspec board. Your subspec board cert depends on your IM board unless you deactivate it! Keeping it only results in pain

See what happened to me⬇️

Remember ABIM is closed after hours and on weekends which is they very time they expect you to complete your MOC and not play with your kids.

The professional journey of Kelly E. McCann, MD, PhD, has been shaped by personal connections to breast cancer, a desire to integrate scientific inquiry with patient care, and a commitment to research in translational oncology. Kelly McCann, MD, PhD #bcsm #oncology onclive.com/view/mccann-on…

El tiempo dirá si al final nos valió lo dolido...

Dr. Mateo Mejia (Mateo Mejia) shares the importance of #MyelomaAwarenessMonth and how new treatment options have improved quality of life for those with #MultipleMyeloma .

Lo más extraño que existe en la Naturaleza es el ser humano. Se reconoce en el hecho de que aun siendo parte de ella la quiere destruir, y ya va muy adelantado en su empeño. (Ricardo Bada, citado por Alfonso Armada)

Another fantastic interview with Kelly E. McCann, MD, PhD, of UCLA Health is in the books! To learn more about her unique experiences as a woman in oncology, check out our website. PER #WomeninOnc #MBCC24 #bcsm

Minuto de salud con Univision LA y . hablado sobre los síntomas del cancer colorectal
vimeo.com/916824091/f879…